Successful treatment of porocarcinoma with maxacalcitol and imiquimod

Nagasawa, Tomoya; Hirata, A.; Niiyama, Shiro; Enomoto, Yasunori; Fukuda, Hidetsugu

doi:10.1111/dth.12830

Cited by 5 publications

(4 citation statements)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an alternative to surgical treatment or as adjuvant therapy, various treatment regimens including CHT (single‐agent or multi‐agent), radiotherapy, electrochemotherapy, and maxacalcitol/imiquimod have been reported with varying response 70,83 …”

Section: Discussionmentioning

confidence: 99%

“…The remaining 116 EPC cases of the head and neck from 90 studies were included in the meta‐analysis. The studies consist of 77 single case reports 7‐14,21,25‐93 and 13 case series with an average of three cases 20,23,24,94‐103 . Additionally, four EPC cases of the University Hospital of the Medical University of Vienna and Evangelical Hospital Vienna could be included in the meta‐analysis.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Eccrine porocarcinoma of the head and neck: Meta‐analysis of 120 cases

Janik

Liu

et al. 2020

Head & Neck

View full text Add to dashboard Cite

Background The aim of the study is to analyze potential prognostic factors and to evaluate therapy strategies regarding clinical outcome in patients with eccrine porocarcinoma (EPC) of the head and neck. Methods One hundred and sixteen EPC cases from ninety studies and four authors' EPC cases were included in the meta‐analysis. Results At an average follow up of 20.48 months, the 3‐year overall survival and regional recurrence rate were 70.3% and 19.0%, respectively. Patients without surgical treatment had a significantly worse 3‐year overall survival. Mohs microscopic surgery led to significantly less occurrence of regional recurrences compared to wide excision. An ulcerating lesion, high mitotic activity, and lymphovascular invasion were significant prognostic factors. Conclusion Surgical resection is the cornerstone in the therapy of EPC and represents the therapeutic modality that offers the best chance of disease‐free survival. Due to the high probability of recurrence, close follow‐ups are strongly recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Eccrine porocarcinoma of the head and neck: Meta‐analysis of 120 cases

Janik

Liu

et al. 2020

Head & Neck

View full text Add to dashboard Cite

show abstract

“…Mohs surgery remains the gold standard. There are studies highlighting the efficacy of local treatments at an early stage, such as the application of imiquimod and maxacalcitol (a vitamin D derivative) 4 or the use of intralesional interleukin 2 5 or photodynamic therapy. 6 …”

Section: Discussionmentioning

confidence: 99%

Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab

Benhayoun,

Duval Modeste,

Tamarit

et al. 2024

JAAD Case Reports

View full text Add to dashboard Cite

“…Additionally, other alternatives have shown promising results including chemotherapy, radiotherapy, and electro-chemotherapy. There are multiple case reports demonstrating great clinical outcomes from different chemotherapy treatments such as maxacalcitol/imiquimod, docetaxel, or a combination of 5-fluorouracil, cisplatin, doxorubicin, vincristine, and mitomycin [1,[5][6][7]. Another option oncologists are exploring is immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Metastatic Porocarcinoma Effectively Managed by Pembrolizumab

Singh¹,

Nguyen²,

Everest³

et al. 2021

Cureus

View full text Add to dashboard Cite

Eccrine porocarcinoma (EPC) is a rare malignancy of the sweat glands. Currently, there is no standard algorithm for its presentations, diagnosis, and management. However, immunotherapy is an emerging option that may be crucial to the treatment of EPC. This report presents a case of a 79-year-old male who had a skin biopsy of an anterior scalp lesion, which revealed EPC. The patient underwent Mohs micrographic surgery to excise the tumor followed by two additional Mohs surgeries for recurrence and adjuvant radiotherapy. A follow-up positron emission tomography (PET) scan revealed yet another recurrence at the scalp as well as metastases to the left parotid gland and left submandibular lymph node. The patient was started on immunotherapy with pembrolizumab, a programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor, and later achieved remission. This report demonstrates the effective management of EPC using immunotherapy with pembrolizumab.

show abstract

Successful treatment of porocarcinoma with maxacalcitol and imiquimod

Abstract: This is the first report of a case of porocarcinoma that was successfully treated with maxacalcitol and imiquimod.

Cited by 5 publications

References 7 publications

Eccrine porocarcinoma of the head and neck: Meta‐analysis of 120 cases

Eccrine porocarcinoma of the head and neck: Meta‐analysis of 120 cases

Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab

Metastatic Porocarcinoma Effectively Managed by Pembrolizumab

Contact Info

Product

Resources

About